There is one clinical trial.
Feasibility of new biological and histological samples at progression in patients with advanced or metastatic Non Small Cell Lung Cancer (NSCLC). A recent paper from Pr Sequist and coll. has depicted the resistance mechanisms as Thréonine790Methionine (T890M) mutation oncogene cMet (CMet) amplification. Re-biopsies showed in 14% of cases the transition between NSCLC to Small Cells Lung Cancer (SCLC). In 3 patients, resistance mechanisms have disappeared and they became again sensitive to Tyrosine Kinase Inhibitors (TKIs). It is mandatory to have a better description to natural history of the disease. This study will be conducted by the Groupe Français de Pneumo Cancérologie (GFPC) up to 100 patients during 18 Months. Each center will have to define if re-biopsies are possible or not and explain why not.
has depicted the resistance mechanisms as Thréonine790Methionine (T890M) mutation oncogene cMet (CMet) amplification. --- T890M ---
Description: Feasibility of re-biopsies in patients with advanced or metastatic NSCLC after progression of disease under treatment. If the re-biopsy could not be performed : reason of no re-biopsy. If the biopsy could be performed : site and method of rebiopsy.Measure: Feasibility of re-biopsies Time: 18 months / 100 patients
Description: Comparison of types and numbers of resistances before treatment (on the first biopsy) and after treatement (on the re-biopsy). Appearance and/or disappearance of some resistances.Measure: Type of resistance Time: 18 months/100 patients
Description: Description of population: age, performans status, smoking status, sex (number, medium, maximum, minimum). Description of treatment: chemotherapy (type and products), radiotherapy (site), surgery (site)Measure: Disease management Time: 18 months / 100 patients
Description: Description and comparison of histology on the first biopsy and on the rebiopsyMeasure: Biological history of the disease Time: 18 months / 100 patients